A
AAIPharma Services
Drug product development services covering drug product testing, formulation, manufacturing and packaging
About AAIPharma Services
Founded in 1979, AAIPharma began its journey as a specialty pharmaceutical company focused on developing and acquiring branded products. The company provided a range of services, including formulation development, analytical testing, and manufacturing, supporting drug development from the laboratory to commercialization. An early leader for the company was Frederick D. Sancilio, who served as Executive Chairman and Chief Scientific Officer. A pivotal moment in the company's story occurred in late 2013 when AAIPharma Services announced its intent to merge with Cambridge Major Laboratories (CML), a company specializing in active pharmaceutical ingredient (API) development and manufacturing. This strategic move aimed to create a comprehensive, integrated service provider for the pharmaceutical industry. Patrick Walsh, then CEO of AAIPharma, was appointed CEO of the newly merged entity. This merger of two highly respected firms created a powerful new player in the contract development and manufacturing organization (CDMO) space. The combined company offered an end-to-end solution, from API and solid-state chemistry to finished dosage form manufacturing and packaging. In March 2016, the unified company rebranded, leaving behind its legacy names to become Alcami, a name reflecting its transformation. Today, Alcami operates as a leading CDMO, serving pharmaceutical and biotech companies worldwide.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 1979
- Headquarters
- Wilmington, United States
- Employees
- 226
- Open positions
- None listed
- Dealroom signal
- 55.5/100
- Industry
- Health
- Sector
- Health, Biotechnology
- Client focus
- b2b
- Investment activity
- 1 company, latest Nov 2000
- Capital deployed
- $46M
- Preferred round
- SERIES E
Latest news
Press, funding announcements and product moves mentioning AAIPharma Services.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VC✓Equity / VC | Jan 2012 | $20M | — | Undisclosed | — |
| ACQUISITION✓Exit | Jul 2005 | $209M | $209M | Xanodyne | — |
Growth signals
Latest recorded traffic for AAIPharma Services is 0 monthly website visits, down 100% over the last three months. AAIPharma Services's team grew 0.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors2 additional known investors
Xanodyne
Water Street Healthcare Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AAIPharma Services on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AAIPharma Services’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.